Intracerebral Haemorrhage Clinical Trial
Official title:
Ischaemic Lesions in Acute Intracerebral Haemorrhage: Pathophysiological Investigation Using Novel Multimodal Cerebral and Systemic Haemodynamic Assessments
The aim of this observational study is to determine how and why inadequate brain blood flow occurs after bleeding in patients with intracerebral haemorrhage (ICH). Treatment for strokes caused by burst blood vessels involves reducing blood pressure (BP) to stop the bleeding. However, this reduction in BP may affect blood flow, causing blockages in blood vessels within the brain. Fast breathing also affects brain blood flow. Therefore, participants will be asked to undergo a simple brain blood flow assessment using transcranial Doppler (TCD) within 48 hours upon admission to hospital. Patients will then have a follow-up TCD assessment at 4-7 days post-ICH onset, in addition to an MRI scan at >7 days. This research will help to confirm if blockages after bleeding are caused by reduced blood flow within the brain.
Stroke is the second-leading cause of death worldwide, with high mortality and morbidity rates. One stroke type, intracerebral haemorrhage (ICH), refers to spontaneous, non-traumatic bleeding, within the brain tissue and is the second most common cause of stroke. Although ICH can happen at any age, it is more common over the age of 70. The most common cause of ICH is hypertension, which can cause bursting of cerebral blood vessels, resulting in bleeding within the brain. National and international guidelines strongly advocate systolic blood pressure (BP) lowering in ICH as part of "bundled" care, reducing fluctuations in cerebral blood velocity (CBv). However, despite blood pressure (BP) lowering being deemed clinically safe, no reduction in death or disability at 90 days was demonstrated in two landmark large randomised controlled trials. Moreover, reductions in BP may affect CBv to the whole of the brain, inadvertently causing ischaemic stroke (blockage of the blood supply). Previous literature has identified that mild-to-moderate ICH stroke severity benefits from early and stable BP lowering, but those with excessively systolic high BP (>220 mmHg) prior to lowering suffer significantly higher rates of neurological deterioration. In order to understand the relationship between BP changes and potential clinical benefit in ICH, it needs to be determined if there is a global reduction in brain perfusion which is causing ischaemic lesions in the brain following ICH. Prospective studies have shown impairments in dynamic cerebral autoregulation (dCA), cerebrovascular tone, and cerebrovascular resistance in acute ICH. Moreover, meta-analyses have demonstrated a previously unreported confounder to cerebral autoregulatory function: the presence of an acute reduction in spontaneous CO2 tension after ICH, potentially reflecting spontaneous hyperventilation (measured as partial pressure in arterial blood (pCO2) in patients in intensive care and on the ward). There is no current explanation for the presence of spontaneous hyperventilation post-ICH. However, it has been shown that across a range of end-tidal carbon dioxide (EtCO2) values, cerebral blood flow (CBF), dCA, and other core haemodynamic parameters (arterial BP and heart rate) have a dose-response relationship. Fast breathing is also known to affect CBv. When EtCO2 is low, rapid acute cerebral vasoconstriction can occur - risking acute ischaemic injury. Therefore, in the presence of spontaneous hyperventilation or induced hyperventilation, reductions in brain perfusion through vasoconstriction could risk new or worsened ischaemic insults, particularly in the presence of BP lowering. Whilst the presence of cerebral small vessel disease plays a role in incidence of diffusion-weighted imaging (DWI) lesions after ICH, there have been no mechanistic association studies to date linking key confounding factors: BP lowering, EtCO2 change, dCA, and ischaemic lesions. The investigators aim to perform transcranial Doppler (TCD) to measure CBv in patients with ICH within 48 hours of admission to hospital. These patients would then have a follow-up TCD assessment at 4-7 days post-ICH onset, in addition to a magnetic resonance imaging (MRI) scan (>7 days). Data would be collected and analysed to determine the relationship between cerebral haemodynamics and ischaemic lesions on MRI, post-acute ICH. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06429332 -
International Care Bundle Evaluation in Cerebral Hemorrhage Research
|
Phase 4 | |
Completed |
NCT01563445 -
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
|
Phase 2 | |
Completed |
NCT00127283 -
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
|
Phase 3 | |
Completed |
NCT03737344 -
BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage
|
Phase 2 | |
Completed |
NCT02162017 -
Head Position in Stroke Trial (HeadPoST)
|
N/A | |
Completed |
NCT03385928 -
STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units
|
Phase 2 | |
Recruiting |
NCT06067750 -
Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
|
||
Active, not recruiting |
NCT01937065 -
Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study
|
N/A | |
Active, not recruiting |
NCT01947361 -
Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber)
|
N/A | |
Completed |
NCT00266006 -
Factor VIIa in Acute Intracerebral Haemorrhage
|
Phase 2 | |
Recruiting |
NCT05369351 -
Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage
|
Phase 2 | |
Recruiting |
NCT05681988 -
Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage (EMINENT-ICH)
|
N/A | |
Completed |
NCT02880878 -
ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)
|
N/A | |
Completed |
NCT02176174 -
Ethnicity and Onset of Cardiovascular Disease: A CALIBER Study
|
N/A | |
Completed |
NCT01702636 -
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial
|
Phase 2 | |
Active, not recruiting |
NCT01320423 -
Surgical Trial in Lobar Intracerebral Haemorrhage
|
N/A | |
Completed |
NCT00426803 -
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
|
Phase 2 | |
Completed |
NCT01566786 -
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage
|
Phase 2 | |
Recruiting |
NCT03044184 -
Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial
|
Phase 3 |